Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus EP/EC as first-line therapy for advanced extrapulmonary neuroendocrine carcinoma
ChiCTR2100047314Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in neuroendocrine carcinoma (NEC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival at 6 months. Started Jun 2021; status: completed.
02
Drugs
camrelizumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on ChiCTR2100047314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047314.